Newsylist real-time news trend intelligence
▲ Peaking Business

Scribe Therapeutics files for IPO in test of public appetite for earlier-stage biotechs

Scribe Therapeutics files for $75 million IPO to test public appetite for early-stage biotechs

5sources
5articles
3velocity
+0%since first seen
2h agofirst detected

Velocity timeline

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

3210Jul 4 07:48Jul 4 09:49 UTC

The brief

Scribe Therapeutics, a biotech company focused on cardiovascular diseases, has filed for a $75 million IPO. The company, based in Alameda, uses gene-editing technology to fight cholesterol.

Coverage from Renaissance Capital, The Business Journals, Investing.com, Moomoo, and Endpoints News highlights Scribe Therapeutics' stockholder list, which includes Eli Lilly. The IPO will be listed on Nasdaq, but coverage does not yet specify when it will take place or how the public will respond.

Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 1h ago.

Quick answers

What is Scribe Therapeutics' focus?

Cardiovascular diseases

How much is Scribe Therapeutics seeking in its IPO?

$75 million

Who is a notable stockholder in Scribe Therapeutics?

Eli Lilly

Coverage (5)

People, places & organizations

Topics

Related trends